Ballicules.com

Sufentanil

SUFENTA

What it isHighly potent mu agonist; anesthesia and neuraxial analgesia.

Why this oneIts potency and lipid solubility suit epidural and intrathecal use in tiny doses.

What limits itRespiratory depression, delayed after neuraxial use. Chest wall rigidity; Schedule II.

FDA-approved for

FDA label

BOXED WARNING Addiction, abuse, and misuse; life-threatening respiratory depression; risks from concomitant benzodiazepine/other CNS depressant use; neonatal opioid withdrawal syndrome with prolonged use in pregnancy.
FDA dosingPopulationStartTargetMax
Analgesia / anesthesia adjunct (IV)Adults1-2 mcg/kg IVindividualized
Labor and delivery (epidural)Adults10-15 mcg with 10 mL bupivacaine 0.125% ± epinephrine

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy Insufficient data; prolonged use may cause neonatal opioid withdrawal syndrome; not recommended during/immediately before labor.

Lactation Monitor infant for excess sedation and respiratory depression; withdrawal can occur if breastfeeding/opioid stopped.

⚠ BOXED WARNINGS

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Sufentanil ballicule

Sufentanil ballicule: receptor binding, kinetics and half-life diagram

Open Sufentanil in the interactive console ↗